147 related articles for article (PubMed ID: 35864593)
1. Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer.
Udagawa H; Takahashi S; Hirao M; Tahara M; Iwasa S; Sato Y; Hamakawa T; Shitara K; Horinouchi H; Chin K; Masuda N; Suzuki T; Okumura S; Takase T; Nagai R; Yonemori K
Cancer Med; 2023 Jan; 12(2):1269-1278. PubMed ID: 35864593
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion Cohort.
Shitara K; Hirao M; Iwasa S; Oshima T; Komatsu Y; Kawazoe A; Sato Y; Hamakawa T; Yonemori K; Machida N; Yuki S; Suzuki T; Okumura S; Takase T; Semba T; Zimmermann B; Teng A; Yamaguchi K
Clin Cancer Res; 2023 Apr; 29(8):1460-1467. PubMed ID: 36730323
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Nishio M; Murakami S; Kawakami H; Okishio K; Tamiya M; Kobayashi H; Fujimoto D; Sugawara S; Kozuki T; Oya Y; Izumi H; Shiroyama T; Satouchi M; Yamamoto N; Kaname S; Matsuoka D; Otake Y; Takase T; Semba T; Azuma K
Cancer Res Commun; 2024 Jan; 4(1):226-235. PubMed ID: 38181055
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
Ida H; Shimizu T; Nishino M; Nakamura Y; Yazaki S; Katsuya Y; Sato J; Koyama T; Iwasa S; Sudo K; Kondo S; Yonemori K; Shitara K; Shiono S; Matsuoka D; Yasuda K; Otake Y; Suzuki T; Takase T; Takashima S; Yamaguchi K; Semba T; Yamamoto N
Cancer Res Commun; 2023 Jul; 3(7):1189-1199. PubMed ID: 37435605
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Kawazoe A; Yamamoto N; Sugimoto N; Kawakami H; Oshima T; Yamaguchi K; Hino K; Hirao M; Kurokawa Y; Kawakami T; Tsuda M; Hara H; Kaname S; Matsuoka D; Otake Y; Yasuda K; Takase T; Takashima S; Semba T; Muro K
Clin Cancer Res; 2024 Apr; 30(7):1264-1272. PubMed ID: 38295160
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Masuda N; Ono M; Mukohara T; Yasojima H; Shimoi T; Kobayashi K; Harano K; Mizutani M; Tanioka M; Takahashi S; Kogawa T; Suzuki T; Okumura S; Takase T; Nagai R; Semba T; Zhao ZM; Ren M; Yonemori K
Eur J Cancer; 2022 Jun; 168():108-118. PubMed ID: 35500404
[TBL] [Abstract][Full Text] [Related]
7. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
11. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
Paz-Ares L; Spigel DR; Chen Y; Jove M; Juan-Vidal O; Rich P; Hayes T; Calderón VG; Caro RB; Navarro A; Dowlati A; Zhang B; Moore Y; Yao X; Kokhreidze J; Ponce S; Bunn PA
Cancer; 2022 May; 128(9):1801-1811. PubMed ID: 35195913
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
Gitlitz BJ; Tsao-Wei DD; Groshen S; Davies A; Koczywas M; Belani CP; Argiris A; Ramalingam S; Vokes EE; Edelman M; Hoffman P; Ballas MS; Liu SV; Gandara DR
J Thorac Oncol; 2012 Mar; 7(3):574-8. PubMed ID: 22198425
[TBL] [Abstract][Full Text] [Related]
13. PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Ferrarotto R; Swiecicki PL; Zandberg DP; Baiocchi RA; Wesolowski R; Rodriguez CP; McKean M; Kang H; Monga V; Nath R; Palmisiano N; Babbar N; Sun W; Hanna GJ
Oral Oncol; 2024 Feb; 149():106634. PubMed ID: 38118249
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
15. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
[TBL] [Abstract][Full Text] [Related]
18. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.
Even C; Lassen U; Merchan J; Le Tourneau C; Soria JC; Ferte C; Ricci F; Diener JT; Yuen E; Smith C; Oakley GJ; Benhadji KA; Massard C
Invest New Drugs; 2020 Apr; 38(2):402-409. PubMed ID: 30953269
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
